These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 20664472)

  • 21. [Gastrointestinal neuroendocrine tumors: update 2024].
    Lahner H; Pavel M
    Inn Med (Heidelb); 2024 Jul; 65(7):664-671. PubMed ID: 38900278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine tumour management: a team approach.
    Banfield A; Green S; Ramage JK
    Hosp Med; 2005 Jan; 66(1):37-42. PubMed ID: 15686165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
    Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
    Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Sigel CS
    Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
    Asa SL; La Rosa S; Basturk O; Adsay V; Minnetti M; Grossman AB
    Endocr Pathol; 2021 Mar; 32(1):169-191. PubMed ID: 33459926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
    Strosberg JR; Cheema A; Kvols LK
    Cancer Control; 2011 Apr; 18(2):127-37. PubMed ID: 21451455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.
    Pape UF; Böhmig M; Berndt U; Tiling N; Wiedenmann B; Plöckinger U
    Ann N Y Acad Sci; 2004 Apr; 1014():222-33. PubMed ID: 15153439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Guidelines for gastroenteropancreatic neuroendocrine tumors--what is new? What should be incorporated in daily therapeutic decisions?].
    Grabowski P; Hörsch D
    Z Gastroenterol; 2015 Oct; 53(10):1194-200. PubMed ID: 26480056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    Wang SC; Fidelman N; Nakakura EK
    Semin Oncol; 2013 Feb; 40(1):69-74. PubMed ID: 23391114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interpretation of updated international guidelines for diagnosis and treatment of gastroenter-opancreatic neuroendocrine neoplasms].
    Chen LH; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):843-848. PubMed ID: 34674457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract]   [Full Text] [Related]  

  • 33. Current Concepts in the Management of GEP-NETs: Introduction.
    Iyer R
    Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):3-4. PubMed ID: 27167990
    [No Abstract]   [Full Text] [Related]  

  • 34. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
    Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
    Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.
    Khasraw M; Ananda S; Michael M
    Expert Rev Anticancer Ther; 2016; 16(4):391-401. PubMed ID: 26808925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Grading of neuroendocrine tumors].
    Saeger W; Schnabel PA; Komminoth P
    Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poorly Differentiated Neuroendocrine Tumors.
    Eads JR
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):151-62. PubMed ID: 26614374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment].
    Klöppel G; Rindi G; Perren A; Komminoth P; Klimstra DS
    Pathologe; 2010 Sep; 31(5):353-4. PubMed ID: 20809402
    [No Abstract]   [Full Text] [Related]  

  • 39. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
    Kim JY; Hong SM
    Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.